Yarrow Bioscience (NASDAQ:YARW – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Risk & Volatility
Yarrow Bioscience has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500.
Valuation & Earnings
This table compares Yarrow Bioscience and Pharming Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Yarrow Bioscience | $570,000.00 | 83.16 | -$26.48 million | ($14.64) | -1.21 |
| Pharming Group | $376.13 million | 2.45 | $2.85 million | $0.32 | 40.73 |
Pharming Group has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Yarrow Bioscience and Pharming Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
| Pharming Group | 6.23% | 8.70% | 4.93% |
Analyst Recommendations
This is a summary of current ratings for Yarrow Bioscience and Pharming Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Yarrow Bioscience | 1 | 0 | 3 | 0 | 2.50 |
| Pharming Group | 1 | 1 | 3 | 0 | 2.40 |
Yarrow Bioscience currently has a consensus target price of $59.00, suggesting a potential upside of 232.34%. Pharming Group has a consensus target price of $39.67, suggesting a potential upside of 204.31%. Given Yarrow Bioscience’s stronger consensus rating and higher probable upside, research analysts clearly believe Yarrow Bioscience is more favorable than Pharming Group.
Summary
Pharming Group beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.
About Pharming Group
Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
